Volume : 10, Issue : 01, January – 2023



Authors :

Ishwar.P.Kokate, Dr.V.Paithankar, Dattahari.N.Dhage, Komal.R.Thakre

Abstract :

Parkinsonism is one of the commonest neurodegenerative diseases, which is characterized by a selective and progressive degeneration of dopaminergic neurons, causing a series of symptoms which might ultimately induce programmed cell death, Although the etiology of Parkinsonism remains unknown, recent studies have suggested that oxidative stress (OS), produces apoptosis which results in mitochondrial defects, neuroinflammation may also play important roles in its pathogenesis.Recently, considerable attention has been paid to utilize bio friendly and eco-friendly plant-based products for the prevention, cure and treatment of Neurodegenerative disease. This article reviews herbs that have been documented to have a neuroprotective effect in in-vitro and in-vivo parkinson’s disease (PD) model systems. We summarized the anti-parkinsonian activities of herbs according to their genera. Plants corresponding to 47 genera were included in this review. These herbal medicines can be a substitute and precious source for anti-parkinsonian drug discovery. The plant species in these families and genera whose pharmacological actions have been well characterized could possibly be good candidates for further studies to assess its ability to protect against neurodegenerative disease and potentially extend lifespan.
Keywords: Parkinson’s disease, Neuroprotective, Antioxidant, Antiapoptotic, Herbal

Cite This Article:

Please cite this article in press Ishwar.P.Kokate et al A Brief Review On: Herbal Treatment Of Parkinson’s Disease.,Indo Am. J. P. Sci, 2023; 10(01).

Number of Downloads : 10


1. Speciale SG. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol Teratol, 24, 2002, 607-20.
2. Abbas N, Lucking CB, Ricard S, Durr A, Brice A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s disease genetics study group and the European consortium on genetic susceptibility in Parkinson’s disease. Human Molecular Genetics,8(4),1999,567–74.
3. Oliveri RL, Zappia M, Annesi G, Bosco D, Quattrone A. The parkin gene is not involved in late-onset Parkinson’s disease. Neurology, 57(2), 2001, 359– 62.
4. Rajput AH. Frequency and cause of Parkinson’s disease.Can J Neurol Sci,19 (1 suppl), 1992, 103–07.
5. De Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurology,54 (11 suppl 5), 2000, S21–23.
6. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology, 55, 2000, 1358–63
7. oewe W (2006) The natural history of Parkinsonʹs disease. J. Neurol. 253 Suppl 7: VII2‐VII6.

8. AndlinSobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the brain in E urope. Eur. J. Neurol. 12 Suppl 1: 1‐27
9. Zheng GQ. Therapeutic history of Parkinson’s disease in Chinese medical treatises. Journal of Alternative and Complementary Medicine. 2009;15:1223–1230.
10. Li Q, Zhao D, Bezard E. Traditional Chinese medicine for Parkinson’s disease: a review of Chinese literature. Behavioural Pharmacology. 2006;17:403–410.
11. Zhang L, Liu SM. Recent developments of traditional Chinese medicine in treatment of Parkinson disease. Chinese Journal of Clinical Rehabilitation. 2006;10:152–154.
12. Chung V, Liu L, Bian Z, Zhao Z, Fong WL, et al. Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: A systematic review. Movement Disorders. 2006;21:1709– 1715.
13. Yang ZM, Tang XJ, Lao YR. Systematic evaluation on clinical literature related with treatment of Parkinson’s disease with traditional Chinese medicine. Chinese Journal of Integrated Traditional and Western Medicine. 2005;25:612–615.
14. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1988;51:745–752.
15. Wang XD. Diagnosis and differential diagnosis for Parkinson’s disease and Parkinsonism. Chinese Journal of Neurology and Psychiatry. 1985;18:256.
16. Ernst E, Pittler MH, Wider B, Boddy K. CHAPTER 1 General issues. 2008. Oxford Handbook of Complementary Medicine: Oxford University Press.
17. Ernst E, Pittler MH, Wider B, Boddy K. SECTION 3 Therapies. 2006. The Desktop Guide to Complementary and Alternative Medicine: Elsevier Ltd.
18. Higgins J, Green Se. 2008. (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]: The Cochrane
19. Serrano-Duenas M, Cardozo-Pelaez F, Sanchez-Ramos JR. Effects of Banisteriopsis caapi extract on Parkinson’s disease. Scientific Review of Alternative Medicine. 2001;5:127–

20. Cui L, Yu X-d, Cui J. Clinical Observation on Effect of Combined Therapy of Bushen Pingchan Recipe and Medopa Tablet in Treating Parkinson’s Disease. Chinese Journal of Integrated Traditional and Western Medicine. 2003;23:504–507. [Google Scholar]
21. Zhao H, Li WW, Gao JP. Clinical trial on treatment of Parkinson’s disease of Gan-Shen yin deficiency type by recipe for nourishing Gan-Shen. Chinese Journal of Integrated Traditional and Western Medicine. 2007;27:780–784. [PubMed] [Google Scholar]
22. Liu H. Clinical observation on the 45 cases of Parkinson’s Disease patients treated by Budushujingxifengtang with integrative medicine. Yellow River Medicine. 1994;3:72–73. [Google Scholar]
23. Dou YQ, Yang MH, Liu Y, Wei ZM. Curative effect of integrated traditional Chinese medicine and western medicine for treatment of patients with Parkinson disease:A control study. Chinese Journal of Clinical Rehabilitation. 2006;10:6–8. [Google Scholar]
24. Carroll CB, Wroath C, Parkin SG, Hobart J, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology. 2004;63:1245– 1250. [PubMed] [Google Scholar]
25. Yang MJ. Clinical assessment of the effectiveness of Chaihushugansan for the depressive symptoms in Parkinson’s disease. Guangming Journal of Chinese Medicine. 2010;25:31–
32. [Google Scholar
26. Finkel, Richard; Clark, Michelle A.; Cubeddu, Luigi X, Lippincott’s Illustrated Reviews: Pharmacology, 4th Edition, Pg no.156-163.
27. Takahiko Fujikawaa,, Shinji Miguchia, Nariyasu Kanadaa, Naoya Nakaia, Masato Ogataa, Ikukatsu Suzukib, Kunio Nakashimac Acanthopanax senticosus Harms as a prophylactic for MPTPinduced Parkinson’s disease in rats, Journal of Ethnopharmacology 97, 2005, 375–381.
28. Srinivasagam RajaSankara, Thamilarasan Manivasagam, Venkatachalam Sankar, Seppan Prakash, Rathinasamy Muthusamyd, Arumugam Krishnamurti, Sankar Surendran, Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse, Journal of Ethnopharmacology 125, 2009, 369–373.
29. Jin Sup Shima, Hyo Geun Kima, Mi Sun Jua, Jin Gyu Choia, Seo Young Jeongb,c, Myung Sook Oha, Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6- hydroxydopamine model of Parkinson’s disease, Journal of Ethnopharmacology 126,2009, 361– 365
30. Muzamil Ahmad, Seema Yousuf, M. Badruzzaman Khan , Md. Nasrul Hoda , Abdullah Shafique Ahmad, Mubeen Ahmad Ansari, Tauheed Ishrat, Ashok Kumar Agrawal, Fakhrul Islam, Attenuation by Nardostachys jatamansi of 6-hydroxydopamineinduced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies, Pharmacology, Biochemistry and Behavior 83,2006,150–160
31. Su Kima, Sushruta Koppulaa, Pyo-Jam Parka, Ee Hwa Kimb, Chan Gil Kima, Wahn Soo Choic, Kwang Ho Leea, Dong-Kug Choia Chrysanthemum morifolium Ramat (CM) extract protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity, Journal of Ethnopharmacology 126, 2009,447–454.
32. Mi Sun Ju , Hyo Geun Kim , Jin Gyu Choi , Jong Hoon Ryu , Jinyoung Hur , Youn Jung Kim
, Myung Sook Oha, Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson’s disease models, Food and Chemical Toxicology 48,2010, 2037–2044.
33. Deyse Valverde G. De Andradea, Diêgo Madureira de Oliveriaa, George Barretoa, Laura-Aon Bertolinob, Ezequiel Saracenob, Francisco Capanib, Lisandro Diego Giraldeza, Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenoneinduced apoptosis in human neuroblastomas SHSY5Y cells, Brain Research 1 1 9 8, 2 0 0 8 , 1 8 8 – 1 9 6
34. M.I. Sa´nchez-Reus, M.A. Go´mez del Rio, I. Iglesias , M. Elorza, K. Slowing, J. Benedı, Standardized Hypericum perforatum reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats, Neuropharmacology 52,2007, 606-616.
35. M. Mohanasundari, M.S. Srinivasan , S. Sethupathy , M. Sabesan, Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice, Journal of the Neurological Sciences 249,2006,140–144.
36. Hua Ana, In Su Kima, Sushruta Koppulaa, Byung Wook Kima, Pyo Jam Parka, Beong Ou Limb, Wahn Soo Choic, Kwang Ho Leea, Dong Kug Choia, Protective effects of Gastrodia elata Blume on MPP+-induced cytotoxicity in human dopaminergic SH-SY5Y cells, Journal of Ethnopharmacology 130,2010, 290–298.
37. Nagaraja Haleagrahara and Kumar Ponnusamy, Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawlwy rats, J.toxicol.Sci vol.35, 2010, 41-47.
38. Mi Sun Ju , Pyeongjae Lee , Hyo Geun Kim , Ki Yong Lee, Jinyoung Hur , Seung-Hun Cho , Sang Hyun Sung, Myung Sook Oha, Protective effects of standardized Thuja orientalis leaves against6- hydroxydopamine-induced neurotoxicity in SH-SY5Y cells, Toxicology in Vitro 24
,2010, 759–765.
39. A. Pinna, S. Pontis, N. Schintu, N. Simola, S. Kasture,M. Morelli. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease, Poster presentations / Parkinsonism and Related Disorders 15S2 , 2009,S29–S199.
40. Muzamil Ahmad, Sofiyan Saleem, Abdullah Shafique Ahmad,Seema Yousuf, Mubeen Ahmad Ansari, M Badruzzaman, Ginkgo biloba affords dosedependent protection against 6- hydroxydopamineinduced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences, Journal of Neurochemistry, 93, 2005,94– 104.
41. L.C.S.L. Morais, L.J. Quintans-Ju´ nior, C.I.F. Franco, J.R.G.S. Almeida, R.N. Almeida Antiparkinsonian-like effects of Plumbago scandens on tremorine-induced tremors methodology Pharmacology, Biochemistry and Behavior 79 ,2004, 745–749.
42. Amar Jyoti, Deepak Sharma. Neuroprotective role of Bacopa monniera extract against aluminiuminduced oxidative stress in the hippocampus of rat brain, NeuroToxicology 27,2006,451–457.
43. Ravikumar Hosamani, Muralidhara. Neuroprotective efficacy of Bacopa monnieri against rotenone induced oxidative stress and neurotoxicity in Drosophila melanogaster, NeuroToxicology 30,2009,977–985.
44. Chien-Min Lin, Rong-Dih Lin , Shui-Tein Chen, Yi-Pei Lin , Wen-Ta Chiu, Jia-Wei Lin, Feng-Lin Hsu , MeiHsien Lee. Neurocytoprotective effects of the bioactive constituents of Pueraria thomsonii in 6- hydroxydopamine (6-OHDA)-treated nerve growth factor(NGF)-differentiated PC12 cells, Phytochemistry, 2010
45.lobal, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953. doi:10.1016/S1474-4422(18) 30295-3
46. Marras C, Beck JC, Bower JH, et al; Parkinson’s Foundation P4 Group. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0
47. Kouli A, Torsney KM, Kuan WL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane, Australia: Codon Publications; 2018. https://www.ncbi.nlm.nih.gov/ books/NBK536722/. Accessed September 6, 2019. doi:10.15586/codonpublications. parkinsonsdisease.2018.ch1
48. International Parkinson and Movement Disorder Society. Evidence Based Medicine Publications. https://www.movementdisorders.org/MDS/ Resources/Publications-Reviews/EBM-Reviews. htm. Accessed November 14, 2019.
49.A. Lee and R. M. Gilbert, “Epidemiology of Parkinson disease,” Neurologic Clinics, vol. 34, no. 4, pp. 955–965, 2016.
48.D. K. Simon, C. M. Tanner, and P. Brundin, “Parkinson disease epidemiology, pathology, genetics, and pathophysiology,” Clinics in Geriatric Medicine, vol. 36, no. 1, pp. 1–12, 2020.
49. Cabreira and J. Massano, “Parkinson’s disease: clinical review and update,” Acta Médica Portuguesa, vol. 32, no. 10, pp. 661–670, 2019.
50. Hou, X. Dan, M. Babbar et al., “Ageing as a risk factor for neurodegenerative disease,” Nature Reviews. Neurology, vol. 15, no. 10, pp. 565–581, 2019.
51. Zheng CY, Luo XD. Clinical Study on Pabing Recipe III for Treatment of 30 Cases of Parkinson’s Disease. Journal of Traditional Chinese Medicine. 2006;47:516–518.
52. Chen JZ, Jian W, Shi J, Li B, Wu SH. Preliminary Clinical Observation of 60 Cases of Parkinson’ s Disease Mainly Treated by Tonifying Spleen and Kidney. Journal of Chengdu University of Traditional Chinese Medicine. 1999;22:14–15,
53. An LZ. Clinical trial for the treatment of Parkinson’s disease with clearing the heart and resolving phlegm method. Journal of Sichuan of Traditional Chinese Medicine. 2009;27:81–82
54. Wu DH, Zhao RC, Long HJ, Jiang JL, Tang PL, et al. Clinical observation of the effect of Ruogantongluotang: 36 Cases of Parkinson Disease. Guiding Journal of Traditional Chinese Medicine and Pharmacy. 2008;14:24–26.
55. Yuan CX, Zhi HP, Chen SZ, Chen Y, Li J, et al. Clinical multicenter randomized controlled study on treatment of Parkinson’s disease with “Shudi Pingchan Decoction” and western medicine. Shanghai Journal of Traditional Chinese Medicine. 2010;44:3
56. Wang D. Clinical study of Integrative Medicine for treating 31 cases of Parkinson disease. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine. 2009;9:27–28
57. Wang YL. Clininical trial on Shujinjiedutang for the treatment of Parkinson’s disease. Journal of Shandong University of Traditional Chinese Medicine. 2009;33:26–
58. Shen Y, Luo LL. Parkinson’s Disease Treated with Tongxinluo Capsule, Liuwei Rehmannia Root Pill and Madopar. Journal of Zhejiang University of Traditional Chinese Medicine. 2008;32:197–198.
59. Liang JF, Yang LL, Li F. Clinical obserbation of the effectiveness of WuhuZhuifengsan for the treatment of levodopa induced dyskinesia in 30 cases. Liaoning Journal of Traditional Chinese Medicine. 2008;35:82–83.
60. Li XX. Clinical study on 27 cases of Parkinson’s disease treated with Xifengdingzhantang and Madopar. Traditional Chinese Medicinal Research. 2008;21:32–33.